2012 will speed up for medical devices, medicine their restructuring and mergers

Since enter into New Year , plus the cure, speeding up the medical instruments and medical their merger and reorganization, the department medical equipment manufacturers also challenge and power. And the A share market of the medicine for the listed company, will create new opportunities.

     Work on promoting mergers and acquisitions
      A few days ago, Chinese medicine, topfond pharmaceutical and disclosure matters assets restructuring progress matters. Announcement said the material assets reorganization for actual controller general matters technology group, China pharmaceutical and topfond pharmaceutical between the assets reorganization. And on January 10,, Shanghai pharmaceutical [10.74 1.51% shares it research report] subsidiary company of Chinese and western Shanghai 3 d pharmaceutical Co., LTD. And Shanghai gold and biological technology Co., LTD. Signed a investment agreement, Chinese and western 3 d get gold and biological 51% equity, will strengthen the investment of field against tumor API.

      China pharmaceutical business association FuMingZhong told reporters, promote m&a is the pharmaceutical business focus. At the same time, the reporter understands, 2012 years between the medical enterprise m&a in policy guidance will be under more in-depth, this year will be the medical enterprise quickly do mass, the fast development of the important strategic years.
      Improve industry concentration
       According to FuMingZhong introduction, the next few years will be the medicine industry mergers and acquisitions climax period. Internationally, industrialization of developed countries in medical business concentration more than 90%, and the drugs wholesale integration fast in retail, pharmaceutical will be relatively lags behind wholesale. In the new medical environment, countries want to speed up the industrial concentration enhancement and upgrade management.

       In addition, the new GMP standards will also push for enterprises to develop m&a. Last December 7, the standing committee of state council for theory through the national drug safety planning (2011 ~ 2015) ", has been clear about the "1025" period of drug safety work overall goals and key tasks, emphasize to 2015, pharmaceutical production must comply with the requirements of GMP 100%, leaving medicine enterprises only four years of time. The state food and drug administration, director of the JiZhaJu king told the press that ascension of the whole trade quality management level is the focus of the implementation of the new GMP. "Hope to through the implementation of the new GMP perfect relevant policy, promote enterprise merger restructuring and industrial structure adjustment. Also hope that the product structure is good, great market potential of the enterprise development."

        In fact, long-term since, our country medicine industry has been in "small, bulk, disorderly and poor" pattern, the industrial concentration is low, the enterprise product homogeneity plagued the problems such as the pharmaceutical industry, intensive operation and unfavourable to reduce production cost was born, but also to market and orderly competition.

       "Through the merger and reorganization and superior bad discard way of the integration of industry chain, to solve the problem of the industrial concentration is low, and promote the rapid development of the industry." China pharmaceutical enterprise association related people say.